STRONG SHAREHOLDER

RETURNS

Over the 3 years to 31 August 2016, our NAV has grown
by 83.7%,compared to 20.4% for the FTSE all share index
and 72.6% for the NASDAQ Biotechnology Index
(GBP denominated)

 

EXPERIENCED

BIOTECHNOLOGY

INVESTMENT TEAM


Its award winning fund managers at SV Health Investors are
scientifically and medically trained with over 60 years of
of experience in this specialist sector between them.

 

MONTHLY PERFORMANCE

RESULTS

We issue our monthly newsletter for investors covering
performance and sector developments.

VIEW MONTHLY NEWSLETTER
 

STRONG SHAREHOLDER

RETURNS

Over the 3 years to 31 August 2016, our NAV has grown
by 83.7%,compared to 20.4% for the FTSE all share index
and 72.6% for the NASDAQ Biotechnology Index
(GBP denominated)

 

EXPERIENCED

BIOTECHNOLOGY

INVESTMENT TEAM


Its award winning fund managers at SV Health Investors are
scientifically and medically trained with over 60 years of
of experience in this specialist sector between them.

 

MONTHLY
PERFORMANCE

RESULTS

We issue our monthly newsletter for investors covering
performance and sector developments.

VIEW MONTHLY NEWSLETTER

Ticker

IBT.L; IBT LN

Net Asset Value (NAV)

£266.4m

Market Share Price

640.0p

NAV Per Share

671.7p

As at market close 17 October 2017


What is International Biotechnology Trust?

International Biotechnology Trust offers investors access to the fast growing biotechnology sector through an actively managed, diversified fund. Its award winning fund managers at SV Health Investors are scientifically and medically trained with over 60 years of experience in this specialist sector between them. As well as investing in a wide ranging portfolio of global quoted biotechnology stocks, we include a small proportion of otherwise inaccessible carefully selected unquoted investments which have the potential to deliver additional returns over the long term. Excellent management teams, unique innovative products and strong potential for outperformance are the key criteria for inclusion in our diversified portfolio of assets.

 

presentationFor further information about the biotechnology sector investment thesis and the Company please refer to our investor presentation.

 

Investor Presentation 


Access to growth and income

International Biotechnology Trust now offers investors the rare combination of high capital growth and sustainable dividend income. The Lead Investment Manager, Carl Harald Janson is celebrating his three year tenure with strong performance versus the benchmark, returning 83.7% (GBP) over that period vs 20.4% (GBP) from the FTSE All-Share and 72.6% (GBP) from the NASDAQ Biotechnology Index.

3 year Return
to 31 August 2016
IBT (NAV)83.7%
NASDAQ Biotechnology Index (GBP)72.6%
FTSE All-Share20.4%
Unusually for a company in a high growth sector, International Biotechnology Trust’s Board has recently announced the introduction of an annual dividend of 4% of the Net Asset Value at each year end payable in semi-annual instalments. The first interim dividend of 11.5p per share was paid to all shareholders on 31 January 2017. The second interim dividend of 11.5p per share was declared on 13 July 2017 and will be paid to all shareholders on the register at the close of business on 4 August 2017. The dividend will be paid on 31 August 2017.

 

 

 

An Introduction to International Biotechnology Trust Plc

Our awards

UK TECH AWARD 2015:
Tech Fund Manager of the Year

INVESTOR CHRONICLE FT 2015:

Best Specialist Fund

MOST SIGNIFICANT CONTRIBUTION AWARD

Won by Portfolio Manager, Kate Bingham, at the European Mediscience Awards in 2016

REGISTRAR
Equiniti Limited

PR AGENCY
Lansons

BROKER
Cenkos Securities

COMPANY SECRETARY
BNP Paribas Secretarial
Services Limited

INVESTMENT MANAGER
SV Health Managers


INVESTMENT MANAGER / AIFM

SV Health Managers LLP manages life sciences investments as the AIFM for International Biotechnology Trust plc (www.ibtplc.com). The investment manager have a breadth of experience across both public and private investing. The majority of investments made are in the public markets, though private or venture capital investments are also made through a relationship with SV Health Investors LLP (www.svhealthinvestors.com) which provides unique deal flow for private company investment opportunities. Together, Janson, Bingham and Craig sit on an investment committee to decide which investments to make for International Biotechnology Trust plc in both public and private companies.

Further information is available at www.svhealthinvestors.com


INVESTMENT MANAGER / AIFM

carl_small

CARL HARALD JANSON
Lead Manager

slide-kate

KATE BINGHAM
Investment Manager

ailsa_small

ALISA CRAIG
Investment Manager

LUCY COSTA DUARTE
Investment Manager

slide-nick

NICK COLEMAN
Head of Finance & Compliance

INVESTMENT MANAGER
SV Life Sciences
Managers LLP


COMPANY SECRETARY

BNP PARIBAS SECRETARIAL SERVICES LIMITED
Susan Gledhill and Gemma Metson


10 Harewood Avenue, London, NW1 6AA
Phone: +44 (0) 20 7410 5971 | Fax: +44 (0) 20 7410 4449
Email: susan.gledhill@uk.bnpparibas.com and gemma.metson@uk.bnpparibas.com
Further information is available at www.securities.bnpparibas.com

COMPANY SECRETARY
BNP Paribas Secretarial
Services Limited


BROKER

CENKOS SECURITIES


Key Contact: Tom Scrivens
6.7.8 Tokenhouse Yard London EC2R 7AS
Phone: +44 (0) 131 220 6939 | Fax: +44 (0) 131 220 2051
Email: info@cenkos.com
Further information is available at www.cenkos.com

BROKER
Cenkos Securities


PR AGENCY

LANSONS


Key Contacts: Caroline Cant and Henrietta Guthrie
24a St John Street London EC1M 4AY
Phone: +44 (0)20 7490 8828 | Fax: +44 (0)20 7490 5460
Email: pr@lansons.com
Further information is available at www.lansons.com

PR AGENCY
Lansons


REGISTRAR

EQUINITI LIMITED


24a St John Street London EC1M 4AY
Shareholder Helpline: 0871 384 2624*
*Calls to this number are charged at 8p per minute from a BT Landline. Other telephone providers may vary. The Helpline is available between 8.30 am and 5.30 pm on Monday to Friday.
Further information is available at www.shareview.co.uk

REGISTRAR
Equiniti Limited

SUBSCRIBE TO OUR NEWSLETTER